HGF

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Retrieved on: 
Wednesday, April 3, 2024
Athira Pharma, HGF, AAN, Nervous system, ALS, American Academy, Annual general meeting, American Academy of Neurology, Pharmaceutical industry

BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal health and slow neurodegeneration, today announced a planned poster presentation at the upcoming American Academy of Neurology (AAN) 2024 Annual Meeting , to be held April 13 – 18, 2024, in Denver, Colorado and online.

Key Points: 
  • BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal health and slow neurodegeneration, today announced a planned poster presentation at the upcoming American Academy of Neurology (AAN) 2024 Annual Meeting , to be held April 13 – 18, 2024, in Denver, Colorado and online.
  • The presentation will highlight preclinical data supporting the continued development of Athira's pipeline of small molecule candidates targeting the neurotrophic hepatocyte growth factor (HGF) system, including fosgonimeton for Alzheimer’s disease, ATH-1105 for amyotrophic lateral sclerosis (ALS), and ATH-1020 for Parkinson’s disease.
  • Athira’s drug development pipeline includes potential first-in-class (fosgonimeton) and next-generation (ATH-1105 and ATH-1020) small molecule drug candidates designed to promote the neurotrophic HGF system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the nervous system.
  • Athira’s drug candidates have distinct properties, which the company believes may be applicable to a broad range of neurodegenerative diseases.

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference

Retrieved on: 
Friday, March 8, 2024
Central nervous system, Toxicity, Research, Pathology, ADAS, HGF, Hepatocyte growth factor, Conference, SHAPE, Doctor of Philosophy, Safety, Dementia, Survival, Athira Pharma, GBA1, Lewy body, Ageing, DSM-IV codes

BOTHELL, Wash., March 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented new clinical and preclinical data further highlighting the therapeutic potential of fosgonimeton at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, being held in Lisbon, Portugal March 5 – 9, 2024.

Key Points: 
  • Fosgonimeton is a potentially first-in-class investigational small molecule designed to positively modulate the hepatocyte growth factor (HGF) system, which can activate neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system.
  • “We believe safety and efficacy outcomes from the exploratory SHAPE Phase 2 clinical trial presented at this year’s AD/PD, along with previous clinical data, support the continued development of fosgonimeton.
  • These findings support the potential therapeutic benefit of modulating the neurotrophic HGF system with fosgonimeton for neurodegenerative diseases.
  • “We’re pleased to be presenting additional preclinical data highlighting the neuroprotective effects of fosgonimeton in models of both Alzheimer’s and Parkinson’s diseases at AD/PD 2024,” said Kevin Church, Ph.D., Chief Scientific Officer of Athira.

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Retrieved on: 
Thursday, February 22, 2024
ACT, ERP, Central nervous system, Dementia, Excitotoxicity, ALS, Research, MNDA, Pathology, Research and development, Inflammation, HGF, Conference, Society, Annual general meeting, Doctor of Philosophy, Frontiers, Biomarker, Administration, Clinical trial, Survival, Investment, Neuroprotection, Three-body problem, G&A, Athira Pharma, Lewy body, Insurance, Pharmaceutical industry

BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2023, and reviewed recent pipeline and business updates.

Key Points: 
  • In December 2023, the Company announced encouraging results from the exploratory Phase 2 SHAPE clinical trial to evaluate fosgonimeton in patients with Parkinson's disease dementia and dementia with Lewy bodies.
  • In May 2023, Athira selected the 40 mg dose for further development and potential regulatory approval.
  • In January 2024, Athira completed enrollment of the LIFT-AD study, randomizing approximately 315 patients in the primary analysis population.
  • In December 2023, Athira announced encouraging results from the exploratory SHAPE Phase 2 clinical trial of fosgonimeton for the potential treatment of Parkinson's disease dementia and dementia with Lewy bodies.

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Thursday, February 8, 2024
Human, Inflammation, Survival, ALS, Athira Pharma, Pathology, Sympathetic nervous system, Frontiers, Vance DeGeneres, AFL, HGF, Doctor of Philosophy, Neuromuscular junction, Plasma, Research, Biomarker

ATH-1105 is a next-generation, orally administered small molecule drug candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system.

Key Points: 
  • ATH-1105 is a next-generation, orally administered small molecule drug candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system.
  • “These data demonstrate that ATH-1105 treatment results in significant, consistent beneficial effects both in cell culture and in vivo models of ALS.
  • “There is an urgent need for new ALS treatment options, particularly those aimed at slowing or stopping neurodegeneration,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
  • These findings further support our plans to progress ATH-1105 into first-in-human studies in the first half of 2024.”

AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Retrieved on: 
Tuesday, January 16, 2024
Ficlatuzumab, Patient, Outline of health sciences, HGF, HNSCC, Survival, Cetuximab, Medicine, Cancer, George Washington School, Optimism, Food, Hepatocyte growth factor, Fast Track, HPV, LG Chem, MPH

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced enrollment of the first patient in the FIERCE-HN trial, a global, multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial evaluating ficlatuzumab in combination with ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with human papillomavirus (HPV)-negative recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Key Points: 
  • BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced enrollment of the first patient in the FIERCE-HN trial, a global, multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial evaluating ficlatuzumab in combination with ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with human papillomavirus (HPV)-negative recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
  • Ficlatuzumab is AVEO’s investigational antibody that targets hepatocyte growth factor (HGF).
  • That designation followed AVEO’s June 2021 announcement of positive results from a randomized phase 2 study of ficlatuzumab alone or in combination with cetuximab in patients with pan-refractory, metastatic HNSCC.
  • “We therefore approach the FIERCE-HN trial with a mix of urgency and optimism, as the combination of ficlatuzumab and cetuximab has the potential to expand the range of viable therapeutic options for this underserved population.”

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Retrieved on: 
Monday, January 8, 2024
ACT, Cognition, Dementia, ALS, Survival, Athira Pharma, Neuropsychiatry, Drug development, Lewy body, Retirement, HGF, MD, Doctor of Philosophy, Inflammation, Biomarker, Investment, Central nervous system, Patient, ERP, SHAPE, Pharmaceutical industry

BOTHELL, Wash., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today provided a clinical pipeline outlook and business update for 2024. 

Key Points: 
  • BOTHELL, Wash., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today provided a clinical pipeline outlook and business update for 2024.
  • Athira’s 2024 Clinical Pipeline Outlook: Status and Upcoming Milestones
    Athira’s drug development pipeline consists of potential first-in-class (fosgonimeton) and next-generation small molecule therapeutic candidates (ATH-1105 and ATH-1020) designed to promote the neurotrophic HGF system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system.
  • In January 2024, Athira announced completion of enrollment in the LIFT-AD study, ultimately randomizing approximately 315 patients in the primary analysis population.
  • Hans Moebius, MD, PhD, is retiring as Chief Medical Officer effective January 5, 2024, and will continue as Athira’s Senior Scientific Advisor.

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Retrieved on: 
Wednesday, January 3, 2024
ACT, Dementia, Athira Pharma, Plasma, Hepatocyte growth factor, HGF, GST, ADAS, Three-body problem, Doctor of Philosophy, Biomarker, Central nervous system, Patient, SHAPE, Pharmaceutical industry

BOTHELL, Wash., Jan. 03, 2024 (GLOBE NEWSWIRE) --  Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced completion of enrollment in the Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease.  

Key Points: 
  • “The successful completion of enrollment in LIFT-AD marks an important milestone for Athira and enables the topline data readout in the second half of 2024,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
  • We also recently reported findings from the exploratory SHAPE Phase 2 clinical trial, which investigated the use of fosgonimeton in patients with Parkinson’s disease dementia and dementia with Lewy Bodies.
  • The results showed positive effects on several cognitive measures in the fosgonimeton 40 mg dose group, which is the same dose being investigated in the LIFT-AD trial.
  • The Phase 2/3 LIFT-AD clinical trial, which targeted an enrollment of 298 patients in the primary analysis population, ultimately enrolled approximately 315 patients with mild-to-moderate Alzheimer’s disease in a 26-week, randomized, double-blind, placebo-controlled clinical trial evaluating once-daily subcutaneous injections of fosgonimeton 40 mg compared to placebo.

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Retrieved on: 
Tuesday, December 12, 2023
Dementia, Athira Pharma, Death, Hepatocyte growth factor, HGF, ADAS, Three-body problem, Doctor of Philosophy, Mitt, Central nervous system, Patient, ERP, SHAPE, Pharmaceutical industry

BOTHELL, Wash., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced findings from the exploratory SHAPE Phase 2 clinical trial to evaluate fosgonimeton (ATH-1017) in patients with Parkinson’s disease dementia and dementia with Lewy Bodies.

Key Points: 
  • Fosgonimeton is a potentially first-in-class, investigational, small molecule designed to positively modulate the hepatocyte growth factor (HGF) system, which can activate neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system.
  • In addition, directional improvements in other cognitive, functional and biomarker measurements were observed in the fosgonimeton 40 mg treatment group.
  • The most common adverse event in the treatment groups was injection site reactions.
  • “More broadly, we are encouraged by the clinical and preclinical evidence that support the potential therapeutic effects of HGF system positive modulation across a wide range of neurodegenerative diseases.”

Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND

Retrieved on: 
Tuesday, November 28, 2023
MNDA, ALS, Survival, Athira Pharma, Biomarker, HGF, Motor Neurone Disease Association, Doctor of Philosophy

BOTHELL, Wash., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that a symposium presentation highlighting data from preclinical studies of ATH-1105 as a potential treatment candidate for amyotrophic lateral sclerosis (ALS) will be delivered at the upcoming Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND , to be held December 6 – 8, 2023 in Basel, Switzerland.

Key Points: 
  • BOTHELL, Wash., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that a symposium presentation highlighting data from preclinical studies of ATH-1105 as a potential treatment candidate for amyotrophic lateral sclerosis (ALS) will be delivered at the upcoming Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND , to be held December 6 – 8, 2023 in Basel, Switzerland.
  • Title: ATH-1105, a small molecule positive modulator of the neurotrophic hepatocyte growth factor system, is neuroprotective when administered prophylactically, therapeutically or in combination with riluzole in the prp-TDP-43 A315T mouse model of ALS
    “We look forward to the presentation of these data, which highlight the potential of ATH-1105 as a treatment for ALS and add to the growing body of scientific and clinical data that support the potential benefits of our small molecule therapeutic candidates targeting the neurotrophic HGF system as novel treatments for neurodegenerative diseases,” stated Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
  • “These data, which include preclinical data showing prolonged survival and demonstrating consistent improvements in motor function, nerve function, biomarkers and nerve morphology in a transgenic mouse model of ALS, strongly support confidence in our plans to advance this program into human clinical studies in the first half of 2024.”

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease

Retrieved on: 
Wednesday, November 15, 2023
Molecule, ISCB Senior Scientist Award, Annual general meeting, HGF, Cell proliferation, Athira Pharma, Neuron, Microglia, LPS, Oxidative stress, Neurogenesis, Neuroinflammation, Society, Pharmaceutical industry, Medical imaging, Neuroscience, Neurotrophic factors

“We continue to build the body of preclinical evidence supporting the continued development of fosgonimeton to treat AD and other debilitating neurodegenerative diseases,” said Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma.

Key Points: 
  • “We continue to build the body of preclinical evidence supporting the continued development of fosgonimeton to treat AD and other debilitating neurodegenerative diseases,” said Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma.
  • “Our latest data demonstrate consistent neuroprotective effects of fosgonimeton and provide insights into the mechanisms by which it preserves neurons from degeneration and reduces neuroinflammation.
  • Wei Wu, Ph.D., Senior Scientist II, Athira Pharma, presented preclinical research demonstrating the cellular mechanisms by which fosgonimeton induces anti-inflammatory effects in BV2 microglia cells.
  • The anti-inflammatory effects of fosgonimeton demonstrated in these models suggest it may have the potential to help reduce neuroinflammation, a key pathological feature of several neurodegenerative diseases.